Trident Lifeline Limited held a physical one-on-one investor meeting on August 20, 2026. The session involved discussions with analysts from Haitong Securities and Latin Manharlal Securities Pvt Ltd regarding the company’s business operations and outlook.

The meeting was conducted in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company officials emphasized that only publicly available information was discussed, ensuring no unpublished price-sensitive information (UPSI) was exchanged.

Meeting Details

The engagement took place in Surat, Gujarat. The following participants were present:

• Haitong Securities: Yashika Pancholi
• Latin Manharlal Securities Pvt Ltd: Bhavin Shah and Nirav Asher

Shravan H Patel, Managing Director of Trident Lifeline, confirmed the disclosure via a letter dated August 17, 2026. The company maintains its registered office in Surat and operates a factory in Sachin GIDC, Surat.

Trident Lifeline Limited reported a significant acceleration in financial performance for the quarter ended June 30, 2026 (Q1FY27), with consolidated revenue rising 43% year-on-year to ₹33.7 crore. The Surat-based pharmaceutical company also saw its consolidated profit after tax (PAT) jump 82% to ₹5.1 crore, marking a strong start to the fiscal year as the business transitions from capital deployment to revenue generation.

The filing, submitted pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights that the company has crossed the ₹100 crore revenue milestone on both standalone and consolidated bases. Chairman Hardik Desai attributed the growth to disciplined investments over the past decade, noting that ongoing operational improvements and a healthy pipeline are driving the next phase of expansion. The company aims to triple its consolidated business over the next three years through sustained execution.

Financial Performance

Consolidated revenue from operations stood at ₹33.7 crore in Q1FY27, compared to ₹23.6 crore in Q1FY26. EBITDA increased 65% year-on-year to ₹8.5 crore, with the EBITDA margin expanding by 334 basis points to 25.3%. Net profit after tax rose sharply to ₹5.1 crore from ₹2.8 crore in the same period last year.

On a standalone basis, revenue grew 43% to ₹26.8 crore, while PAT increased 44% to ₹5.0 crore. Standalone EBITDA was ₹7.2 crore, representing a 26.9% margin, an improvement of 71 basis points over the previous year.

Subsidiary Contributions

Trident Lifeline’s growth is supported by its diversified subsidiary structure. TNS Pharma Private Limited contributed ₹6 crore in FY26 revenue, targeting a steady-state EBITDA margin of 30%. Trident Mediquip Limited reported ₹27 crore in FY26 revenue with a target steady-state EBITDA margin of 24%. Other subsidiaries, including TLL Parenterals Limited and TLL Wellness Limited, are positioned to contribute meaningfully as they move beyond their incubation phases.

What the Numbers Show

The divergence between revenue growth and cost structure indicates improving operational efficiency. While revenue grew 43%, EBITDA grew at a faster pace of 65%, leading to a substantial margin expansion. This suggests that fixed costs are being leveraged effectively as capacity utilization increases. Furthermore, the company’s intrinsic value of registrations stands at approximately ₹80 crore, providing a long-term commercial asset base that supports recurring revenue streams across global markets.